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Background: Prior studies have demonstrated hyporesponsiveness to pneumococcal conjugate vaccines
(PCVs) when administered in the presence of homologous carriage. This may be substantially more
important in Africa where carriage prevalence is high. Deriving a correlate of protection (CoP) for carriage
is important in guiding the future use of extended PCVs as population control of pneumococcal disease by
vaccination is now focused principally on its indirect effect. We therefore explored the complex relation-
ship between existing carriage and vaccine responsiveness, and between serum IgG levels and risk of
acquisition.
Methods: We undertook secondary analyses of data from two previously published clinical trials of the
safety and immunogenicity of PCV in Kenya. We compared responses to vaccination between
serotype-specific carriers and non-carriers at vaccination. We assessed the risk of carriage acquisition
in relation to PCV-induced serum IgG levels using either a step- or continuous-risk function.
Results: For newborns, the immune response among carriers was 51–82% lower than that among non-
carriers, depending on serotype. Among toddlers, for serotypes 6B, 14 and 19F the post-vaccination
response among carriers was lower by between 29 and 70%. The estimated CoP against acquisition ranged
from 0.26 to 1.93 lg/mL across serotypes, however, these thresholds could not be distinguished statisti-
cally from a model with constant probability of carriage independent of assay value.
Conclusion: We have confirmed hyporesponsiveness in an equatorial African setting in both infants and
toddlers. Population responses to vaccination are likely to improve with time as carriage prevalence of
vaccine serotypes is reduced. We have not found clear correlates of protection against carriage acquisi-
tion among toddlers in this population. Assessing the potential of new vaccines through the use of CoP
against carriage is still difficult as there are no clear-cut serotype specific correlates.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The first pneumococcal conjugate vaccine (PCV), which con-
tained seven serotypes, reduced the incidence of pneumococcal
disease and the prevalence of nasopharyngeal carriage in both vac-
cinated and unvaccinated children as well as adults when intro-
duced into routine infant immunisation programme in the USA
in 2000 [1]. The indirect protective effect of PCV is caused by a
vaccine-induced reduction in the risk of acquiring colonisation by
vaccine serotypes (VTs), which leads to a reduction in onward
transmission from young children.
Recently, data have emerged that highlight the complexity of
interactions between pneumococci, the human immune system
and the nasopharynx. Infants carrying serotypes 6B, 19F or 23F
at the time of PCV immunisation have reduced primary IgG
responses to those serotypes [2,3] and this effect persists through
to post-booster responses [4]. Rodenburg and colleagues showed
that, at 24 months of age, children’s responses to PCV against these
three serotypes were reduced if they had carried them at any point
in the 2 years prior to vaccination [5].
PCV responses in African children are generally thought to be
higher than those seen in developed country settings [6–9]. For
instance, the serotype-specific geometric mean fold-rise between
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the time of the first dose and one month after the third dose of PCV
were lower in USA [7] and Finland [9] compared to South Africa [6]
and The Gambia [8]. Nonetheless, in parts of Africa like The Gambia
[10] and Kenya [11,12], carriage rates from very early in life are
extremely high. Given high responses to PCV it is possible that
hyporesponsiveness does not occur, or is immunologically irrele-
vant, in equatorial Africa.
The immunological mechanism that mediates vaccine-induced
protection against colonisation at the mucosal level, or against dis-
ease, is not known. While circulating IgG may have a role in pre-
venting colonisation, as demonstrated in a mouse model in
which antibody blocked colonisation through agglutination [13],
local B cells producing IgG and/or IgA in the nasopharynx may also
be relevant and a role for T cells has also been suggested [14,15].
Nonetheless, to facilitate the licencing of new formulations of
PCV, a single aggregate serological correlate of protection against
invasive pneumococcal disease (IPD), has been derived based on
circulating IgG [16,17]. However, a recent analysis that suggested
correlates of protection (CoP) for IPD vary widely by serotype
[18] has questioned the biological relevance of a single aggregate
CoP common to all serotypes. It is likely that, as with IPD, the
CoP against carriage also vary by serotype.
Numerous assumptions were made during the development
of the common serological CoP and there is equipoise in the sci-
entific community about the relevance of the CoP to carriage and
mucosal disease [19]. For some serotypes, greater concentrations
of serum IgG were likely to be required to protect at mucosal
surfaces (e.g. in the nasopharynx) than in blood [20]. Subsequent
analysis of vaccine-induced antibody and the prevention of car-
riage reinforced the notion that if circulating IgG is indeed a rel-
evant correlate for carriage, remarkably high concentrations are
required to reduce carriage acquisition [21]. Deriving CoP for
carriage would guide the future use of extended PCVs, as popu-
lation control of pneumococcal disease by vaccination is now
focused principally on its indirect effect mediated through car-
riage [22].
We therefore set out to explore both the relationship between
existing carriage and vaccine responsiveness and between serum
IgG levels and risk of acquisition by undertaking new analyses of
two existing field studies of PCV in Kenya, with the following ques-
tions: (i) Does hyporesponsiveness occur in high carriage settings
like Kenya? (ii) If so, can we detect this for serotypes other than
the most common (e.g. 6B, 19F and 23F)? (iii) Is it possible to
derive a serological correlate of protection against carriage acquisi-
tion using vaccine-induced IgG responses detected within random-
ized controlled trials of PCV in Kenya?
2. Methods
2.1. Data
Data from two previously published clinical trials of the safety
and immunogenicity of PCV conducted in Kenya [14,15] were fur-
ther analysed in the current study. The first study (‘‘Newborn
study”) recruited 300 newborns that were randomized to receive
7-valent PCV (PCV7) in one of two vaccine schedules; at 0–10–
14 weeks or at 6–10–14 weeks. The subjects received a PCV7 or
23-valent Pneumococcal Polysaccharide Vaccine (PPV23) booster
dose of at 36 weeks. Serological measurements were made at 0,
6, 10, 14, 18, 36 and 37 weeks and nasopharyngeal carriage ascer-
tained at 18 and 36 weeks. The objectives of this study were to
examine the effect of a newborn vaccination schedule with PCV7
on the development of antibody and carriage prevalence. In the
current analysis we used the carriage data at the time of the boos-
ter (week 36) and the serological measurements at week 36 and
week 37.
The second study (‘‘Toddler study”) recruited 600 children aged
1–4 years to examine the effect of 0, 1 or 2 doses of a 10-valent PCV
(PCV10), on capsular antibody concentrations and nasopharyngeal
carriage. Children were given PCV10 in three different schedules:
Group A received PCV10 at day 0 and day 60; Group B received
PCV10 at day 0 and day 180. Diphtheria-tetanus-pertussis (DTaP)
was given as a control vaccine to group A at day 180 and to Group
B at day 60. A third group, which is not considered in this analysis,
received Hepatitis A virus (HAV) at day 0 and day 180 and DTaP at
day 60. Antibody measurements were made at days 0, 30, 90 and
210 and nasopharyngeal carriage assessed at days 0, 30, 60, 90
and 180. Details of the study have been published elsewhere
[23]. In the current analysis we used carriage data from vaccinees
in Groups A and B at day 0, 60 and 180 (vaccination time points),
and serological measurements 30 days post vaccination i.e. at 30,
90 and 210 days, respectively.
2.2. Analysis
For the newborn study, we calculated the fold-rise in serotype-
specific geometric mean concentrations (GMC) between weeks 36
and 37, separately, for carriers and non-carriers for each of the
seven serotypes in PCV7. The differences between the two groups
(homologous carriers vs. non-carriers) were quantified as ratios
of the GMC fold-rises. These ratios were derived from log-linear
regression models of the booster response taking account the vac-
cine schedule group (6–10–14 vs 0–10–14), type of booster given
(PCV7 vs PPV23) and the baseline log-concentration of IgG, at
36 weeks. Baseline IgG concentrations is adjusted for since individ-
uals with lower concentrations have more room for greater fold-
rise than individuals who already have high concentration at
baseline.
For the toddler study, we pooled paired carriage data and 30-
day serological responses for each of the time points of PCV10 vac-
cination (0, 60 and 180 days). We calculated serotype-specific fold-
rises in IgG concentration 30 days later (at 30, 90 and 210 days).
There were no blood samples at time 60 and 180 by design there-
fore we used the IgG at time 30 to adjust for responses to vaccines
given at 60 and 180 days. We would expect antibody concentra-
tions to decay from day 30 to day 60 (and from day 30 to day
180) at the same rate for subjects in both Group A and Group B;
therefore, the ranks in IgG baseline between time 30 days and
the time of vaccination are likely to be highly correlated, provided
that natural boosting is also distributed equally in both groups. To
assess the impact of carriage at the time of vaccination, GMC fold-
rise ratios between homologous carriers vs. non-carriers were esti-
mated from log-linear serotype-specific regression models of the
individual level fold-rise on the carriage status, taking account of
the vaccine group (Group A and B), age group (12–23, 24–35,
36–47 and 48–59 months), season (month of sample collection)
and pre-vaccine (day 0 or 30) log IgG. We used Generalized Esti-
mating Equations (GEE) to account for the correlations between
the repeated measures within an individual. Data for serotypes
6B, 9V, 14, 19F and 23F were selected for the analysis since they
were the most frequently carried of the 10 vaccine-type serotypes.
As a supplementary analysis, we also calculated the post-
vaccination GMC by pre-vaccination carriage status for both the
newborn and toddler studies.
In order to derive the serotype-specific antibody threshold for
vaccine efficacy against acquisition, we restricted our analysis to
data from the toddler study and, in particular, to toddlers who
were non-carriers at day zero. We compared carriage status at
day-30 against vaccine-induced IgG concentration measured at
day 30. We fitted to these two variables a model that incorporates
a threshold parameter that is estimated through a profile likeli-
hood [24], the a:b model. The model is a step-shaped function
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where the step corresponds to the antibody threshold. Thus, in
addition to the threshold parameter, the model also contains two
parameters for constant but different acquisition probabilities
below and above the threshold. A test for the presence of a thresh-
old was achieved by comparing the a:b model to a model with con-
stant probability of acquisition independent of assay value, using a
likelihood ratio test. Confidence intervals around the threshold
estimates were constructed through bootstrapping.
The a:b model does not allow for adjustment of covariates,
therefore, we also modelled the risk of serotype-specific acquisi-
tion as a continuous function of log-IgG concentration in a Cox pro-
portional hazards model that accounted for age group, carriage of a
heterologous serotype at the point of vaccination, log IgG on the
day of vaccination and season. Non-linear relationship between
the acquisition incidence and log-IgG concentration was allowed
through restricted cubic splines. Having no colonisation by any ser-
otype at day 0 predisposes one to considerably higher risk of
colonisation by an index serotype relative to someone colonised
by a different serotype to the index at day 0, due to serotype com-
petition [25,26]. This was the rationale for including carriage of a
heterologous serotype at the point of vaccination in the model.
3. Results
In the newborn study, 235 pairs of 36- and 37-week samples
were analysed. In these subjects the prevalence of carriage of
PCV7 serotypes at 36 weeks ranged from 0.9% for serotype 23F to
12.8% for serotype 19F. Compared to non-carriers, the GMC fold-
rise between week 36 and week 37 among carriers was substan-
tially lower by a factor of 51–82% (Table 1). The point estimates
of the GMC at post-booster (37 weeks) were higher among non-
carriers at the point of vaccination, except of serotype 18C (Supple-
mentary Table S1).
In the toddler study, between 460 and 480 samples were anal-
ysed depending on serotype. The carriage prevalence at the time of
vaccination ranged from 2.1% for serotype 9V to 8.0% for serotype
19F (Table 2). For serotypes 6B, 14 and 19F the GMC fold-rise post
vaccination among carriers was lower by between 29 and 70%. For
serotype 9V and 23F the GMC fold-rise were 53% and 1% higher
among carriers (Table 2). Except for serotype 9V the point esti-
mates of the GMC post-vaccination were higher among non-
carriers at the time of vaccination (Supplementary Table S2).
We computed the serological threshold for vaccine efficacy
against acquisition among serotype-specific non-carriers at the
first vaccination time-point (day 0) by using their titers and car-
riage status 30 days later in the toddler study. The estimated
thresholds ranged from 0.26 to 1.93 lg/mL across serotypes, how-
ever, a test for the presence of a threshold at these points sug-
gested no significant difference from a model with constant
probability of acquisition independent of assay value (Table 3).
We analysed carriage acquisition as a continuous function of log
IgG. There was no convincing monotonically decreasing rate of car-
riage with increasing log IgG for each of the five serotypes (Fig. 1).
In a situation where a higher level IgG had strong negative impact
on carriage, the prevalence ratios below the average (mean/me-
dian) log IgG would be above 1 and the prevalence ratios above
the average log IgG would be below 1, in the plots.
4. Discussion
While inferior quantitative antibody responses to the colonising
serotypes have been reported amongst children vaccinated with
PCV in Philipines [2], Israel [3] and South Africa [27], none have
studied this phenomenon in high carriage settings such as Equato-
rial Africa. Using data from two clinical trials in Kenya, we have
Table 1
Newborn study. Geometric mean fold rise between 36 and 37 weeks (with 95% confidence limits) stratified by carrier status, as well as the difference in the response between
carriers and non-carriers expressed as a ratio. These ratios, and associated p values were derived from log-linear regression models of the booster response taking account of the
vaccine group (EPI vs newborn), the type of booster given (Pneumococcal polysaccharide vaccine vs Pneumococcal conjugate vaccine) and log IgG in week 36.
Serotype Carriers at 36 weeks Non-carriers at 36 weeks Ratio (95% CIs) for carrier/non-carrier P-value
n GM fold-rise 37/36 Weeks (95% CI) n GM fold-rise 37/36 Weeks (95% CI)
4 0 – 235 4.92 (4.36–5.55) – –
6B 6 2.85 (0.69–11.68) 229 13.52 (11.52–15.88) 0.18 (0.07–0.46) <0.001
9V 4 1.62 (0.64–4.11) 231 5.32 (4.72–6.00) 0.31 (0.14–0.69) 0.005
14 10 1.29 (0.86–1.92) 225 2.79 (2.47–3.15) 0.49 (0.30–0.80) 0.004
18C 3 1.25 (0.87–1.79) 232 7.74 (6.87–8.73) 0.15 (0.05–0.40) <0.001
19F 30 1.91 (1.34–2.73) 204 7.19 (6.11–8.45) 0.32 (0.21–0.48) <0.001
23F 2 3.59 (0.02–663.49) 231 10.33 (8.80–12.14) 0.25 (0.06–1.09) 0.064
n: number of individuals.
Table 2
Toddler study. Geometric mean fold-rise between day 0 to 30 or day 30 to 90/210 stratified by carrier status at the time of vaccination (day 0, 60 or 180), as well as the difference
in the response between carriers and non-carriers expressed as a ratio. The ratios and associated p-values were derived from log-linear serotype specific regression models, using
GEE, of the individual level fold-rise on the carriage status, taking account of the vaccine group (Group A and B), age group (12–23, 24–35, 36–47 and 48–59 months), season
(month of swab) and pre-vaccine (day 0 or 30) log IgG.
Serotype Carriers at point of vaccination Non-carriers at point of vaccination Ratio (95% CIs) for carrier/non-carrier P-value
na GM fold-rise (95% CI) na GM fold-rise (95% CI)
6B 23 1.65 (1.22–2.24) 457 2.35 (2.14–2.59) 0.70 (0.51–0.97) 0.034
9V 10 1.88 (0.98–3.61) 466 3.06 (2.65–3.53) 1.53b (0.89–2.65) 0.119
14 15 3.02 (1.99–4.58) 445 5.32 (4.65–6.10) 0.71 (0.50–1.02) 0.067
19F 38 2.12 (1.57–2.87) 439 7.61 (6.50–8.90) 0.30 (0.19–0.46) <0.001
23F 22 3.39 (1.35–8.47) 455 4.28 (3.66–5.00) 1.01 (0.63–1.63) 0.955
a There are two repeated measures for almost all participants. These numbers reflect the number of samples rather than individuals.
b The reason why the adjusted ratio is above 1 (instead of approx. 1.88/3.06 = 0.61, which is the unadjusted ratio) is because one of the factors adjusted for (pre-vaccine log
IgG) was unevenly distributed among carriers vs. non-carriers; the GMC of pre-vaccine log IgG among carriers was significantly higher at 1.61 compared to 0.49 in non-
carriers. Similar case for 23F.
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confirmed hyporesponsiveness in equatorial Africa in both infants
and toddlers, and for the first time described it in serotype 14.
The reduced immune responses to PCV administered to an indi-
vidual with prevailing carriage may reduce the vaccine’s efficacy.
The clinical implication of this is an increased susceptibility to
acquisition of homologous pneumococcal serotypes, particularly
when the reduction in immune response results in lower than suf-
ficient protection against carriage. Several strategies can be useful
in high carriage settings to counter the effect of hyporesponsive-
ness. The use of a catch-up campaign at the time of PCV introduc-
tion can speed-up the reduction in vaccine-type carriage thus
improving the immune responses in cohorts vaccinated in the sub-
sequent period of reduced carriage. Using a booster dose in the sec-
ond year of life can also be used to overcome hyporesponsiveness
[3]. However, the cost-effectiveness of such strategies needs to be
evaluated to provide further evidence for or against their use.
We assessed the association between IgG concentration and the
incidence of carriage in two ways; using a step function, the a:b
model, which explicitly models a threshold and using a model with
carriage incidence as a continuous function of IgG concentration,
which does not explicitly model a threshold. The second approach
allowed us to study the relation while accounting for potential
confounding factors. The result from each of the approaches is
mutually important and complementary in interpreting results
from the alternative approach.
The CoP for carriage were generally higher than the recently
derived serotype-specific CoP for IPD with the exception of sero-
type 14 (0.26 lg/ml for carriage acquisition vs. 0.46 lg/ml for
IPD) [18]. It is expected that the CoP for carriage should be substan-
tially higher than that for IPD; therefore, the result for serotype 14
is surprising. The evidence for the CoP for carriage being lower is,
however, limited given the wide 95% confidence intervals of the
CoP estimate of this serotype (Table 3) and the function of IgG that
does not show drastic change around the estimated CoP (Fig. 1).
For serotype 9V, all the carriers were above the estimated CoP
against acquisition. This scenario reflects one of the potential prob-
lems with the a:b model, that in the estimation process the inci-
dence below a candidate threshold is not restricted to be higher
than that above it. This requirement is, however, imposed post-
estimation in the test for the existence of a threshold at the esti-
mated value [24], such that the test statistic always yields a non-
significant result in such cases. Whether circulating IgG is the cor-
rect correlate of protection also needs to be considered. The exact
mechanism by which pneumococci are prevented from colonising
the nasopharynx is still unclear.
The licensing of future PCVs will likely take into account the
potential impact on carriage [28]. Therefore, defining the CoP for
carriage would provide a way of assessing the non-inferiority of
new vaccines as has been the case for CoP for IPD [16,17]. However,
until a better understanding of existing CoP for IPD exists this may
be complex. For example, there is limited information to sufficiently
explain why IPD correlates for some serotypes are high and others
low. Consequently, predicting whether the CoP for a novel serotype
will be higher or lower, and by what factor, than available CoP for
other serotypes is difficult. New PCVs might incorporate serotypes
that are carried relatively infrequently further complicating the
use of CoP for carriage. Only one previous study that was conducted
in the United Kingdomhas reported on PCV CoP for carriagewhere a
clear threshold against carriage for a single serotype, serotype 14,
was identified [20]. A second study in the Navajo Nation andWhite
Mountain Apache tribal lands, in USA, did not find identifiable IgG
threshold level that was associated with prevention of carriage
acquisition for all the eight serotypes studied [29].
A limitation of the newborn study is that the period between
booster dose and the assessment of its effect was one week. It gen-
erally takes about 4 weeks for a full immune response following
vaccination. Therefore, what we show is that the impact of pre-
existing carriage on immune response is notable as early as one
week. It is possible that after 4 weeks the final concentrations
between carriers and non-carriers are similar. If that is the case
then the effect of pre-existing carriage is in delaying immune
response. From the toddler study, in which there was sufficient
time-lapse between vaccination and assessment of response, the
final concentrations were still different between carriers and
non-carriers. It is unlikely that the case is different for newborns,
because the mechanism causing hypo-responsiveness should be
similar between the two age groups.
In conclusion, we have confirmed hyporesponsiveness in an
equatorial African setting in both infants and toddlers. Pneumococ-
cal conjugate vaccines have been introduced in many African coun-
tries where carriage is generally high. Hyporesponsiveness might
reduce the vaccine’s effectiveness in the early years of introduction
when the prevalence of vaccine serotypes is still high. If so, the
speed with which vaccine-type carriage prevalence is reduced will
determine how fast improved responses are realised in later years
after vaccine introduction, when cohorts of children with reduced
vaccine-type carriage rates replace the cohorts in high prevalence
period. We did not identify clear correlates of protection against
carriage acquisition among toddlers in this population. Given the
limited information from the few studies that have reported on
correlate of protection against carriage, assessing the potential of
new vaccines through the use of correlate of protection against car-
riage remains difficult, as there are no clear-cut serotype-specific
correlates.
Table 3
Toddler study. The serotype-specific serological thresholds for vaccine efficacy against acquisition for five most commonly carried serotypes at day 0. The thresholds are
computed using a step-shaped function where the step corresponds to the threshold with different infection probabilities below and above the threshold. The threshold with the
highest profile likelihood is chosen as the parameters estimate. Confidence intervals are constructed by bootstrapping.
Serotype Threshold (95% CI) Carriage prevalence Ratioa (95% CI) Test for presence of a thresholdb Goodness of fit p-valuec
6B 0.48 (0.07–2.68) 0.21 (0.04–0.72) 0.079 0.048
9Vd 1.86 (1.86–22.67) – >0.999 0.219
14 0.26 (0.16–14.34) 0.26 (0.04–0.87) 0.542 0.851
19F 1.66 (0.85–6.60) 0.10 (0.00–0.60) 0.171 0.314
23Fe 1.93 (0.09–1.94) 0.00 (0.00–0.00) 0.430 0.625
a Carriage prevalence ratio is the carriage risk above the threshold divided by carriage risk below threshold, the confidence interval is obtained by bootstrapping
b A likelihood ratio test for the presence of a threshold. Achieved by comparing the a:b model to a model with constant probability of infection independent of assay value.
Values above 0.05 indicate no sufficient evidence of a difference in the two models at % level of significance.
c This is the Hosmer and Lemeshow goodness of fit p-value testing the null hypothesis that there is no difference between observed and model predicted values. The test
assesses whether the step function represented by the a:b model is an appropriate representation of infection or whether another relationship such as a gradual one between
titer and infection might be more likely than a stepped relationship. All the p-values, except that for serotype 6B, which is borderline, are above 0.05 indicating insufficient
evidence against the null hypothesis at the 5% level of significance.
d There were no carriers of serotype 9V below the threshold of 1.86 mcg/ml hence the risk ratio was undefined.
e There were no carriers of serotype 23F above the threshold of 1.93 mcg/ml hence the risk ratio was zero.
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Fig. 1. The incidence rate ratio (blue solid line) as a function of log IgG titre (x-axis) for each serotype labeled above the graph. The ratios are between the values of log IgG on
the x-axis relative to someone with the average log IgG. For instance, for serotype 6B, the rate ratio between individuals with log IgG of 3 relative to individuals with the
mean log IgG is slightly below 1 (95% CI: 0.5 to 2). The red dashed lines are the 95%CI bounds of the rate ratio. The three vertical (grey) lines mark the 2.5th, 50th and 97.5th
percentiles of the distribution of log IgG whose density is shown in grey on the x-axis. The green line shows the CoP obtained by the a:b model while the light green shade
around it shows the region covered by the bootstrapped 95%CI of that CoP. The likelihood ratio (LR) test p-value for the significance of log IgG in predicting carriage
acquisition and the test for the presence of a threshold estimated by the a:b model is indicated in the plot. (For interpretation of the references to color in this figure legend,
the reader is referred to the web version of this article.)
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